MARATTO

article · Bulletin of Egyptian Society for Physiological Sciences

Effect of Xanthenone Versus Irisin in Alleviating Renal Ischemic Reperfusion Injury through Modifying the PI3K/AKT/eNOS and TLR-4/NFkB Pathways

2024Open accessSuez Canal University

Abstract

Ischemic reperfusion injury (IRI) in the kidney is a common cause of acute-kidney-injury. Our aim is to compare the effects of Xanthenone /Irisin on alleviating inflammation, cell apoptosis and oxidative stress injury in kidney IRI via modulating the PI3K/Akt/eNOS and TLR4-NFkB pathways. 32 male rats were equally divided into groups: Control, IR, IR treated with (i.v) Xanthenone (10mg/kg), IR treated with (i.p) Irisin (100 µg/kg). Renal functions, blood pressure, renal tissue ACE2, Ang 1-7, inflammatory, oxidative stress and apoptotic markers were evaluated. Also, PI3K/AKT/eNOS and TLR-4 relative mRNA levels in renal tissue were assessed. Also, the protein concentration of pAKT, eNOS, histomorphological, and immunohistochemical analysis were done. In IR group, renal function tests, blood pressure, and apoptotic parameters were elevated. ACE2 and Ang (1-7) tissue levels, relative gene expression of PI3K/AKT/eNOS and TLR-4, the protein concentration of pAKT and eNOS, histomorphological and immunohistochemical analysis of NFkB in renal tissue were all distorted in IR group. However, Xanthenone and Irisin treatments improved renal function, inflammation, and oxidative stress through PI3K/AKT/eNOS and TLR-4/ NFĸB pathway. Moreover, Xanthenone acts through ACE2/Ang (1-7) pathway, while Irisin acts mainly through PI3K/AKT/eNOS and TLR4/NFkB pathway. This may increase the potential for combined Xanthenone and Irisin therapy during conditions of AKI.

Research topics

  • Eicosanoids and Hypertension Pharmacology
  • Adipose Tissue and Metabolism
  • Traditional Chinese Medicine Analysis

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/besps.2024.256207.1160

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.